Blog
RSS FeedPosted by Michael Wonder on 23 Oct 2025
New ICER report shows significant jump in launch prices, exceeding inflation and GDP growth
23 October 2025 - Nearly $1.5 billion could have been saved in one year alone if prices matched ICER value ...
Posted by Michael Wonder on 15 Sep 2025
ICER to undertake special report on Crohn’s disease and ulcerative colitis for CMS as part of public comment process on Medicare drug price negotiations
15 September 2025 - Report to reflect legislative specifications in the Inflation Reduction Act and most recent CMS guidance regarding ...
Posted by Michael Wonder on 19 May 2025
ICER publishes protocol for first annual launch price and access report
19 May 2025 - Report to be issued in October 2025. ...
Posted by Michael Wonder on 10 Apr 2025
ICER releases obesity medications white paper examining strategies to ensure affordable access
9 April 2025 - Paper analyses policy reforms and market actions to achieve affordable and equitable access for GLP-1 obesity ...
Posted by Michael Wonder on 04 Mar 2025
ICER publishes special report on COPD therapies as part of CMS public comment process on Medicare drug price negotiations
3 March 2025 - Report reflects legislative specifications in the Inflation Reduction Act and subsequent CMS guidance. ...
Posted by Michael Wonder on 23 Jan 2025
ICER announces new annual launch price and access report for 2025
22 January 2025 - New report will highlight opportunities to improve affordability and access, and demonstrate the importance of having ...
Posted by Michael Wonder on 20 Dec 2024
ICER publishes fourth annual assessment of barriers to fair access within US commercial insurance prescription drug coverage
19 December 2024 - Most payers evaluated offer fair access across the domains reviewed; findings underscore the need for greater ...
Posted by Michael Wonder on 12 Dec 2024
ICER announces most significant drug price hikes unsupported by new clinical evidence in US
12 December 2024 - Of 10 high expenditure drugs that had substantial 2023 net price increases, five were not supported ...
Posted by Michael Wonder on 18 Sep 2024
The ICER developing special report for submission to CMS as part of public comment process on Medicare drug price negotiations
18 September 2024 - Report to reflect legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding price ...
Posted by Michael Wonder on 05 Jun 2024
ICER publishes protocol for annual assessment of drug coverage policies that present barriers to fair access
5 June 2024 - This year’s analysis will include the top ten commercial formularies by covered lives, and include drugs ...
Posted by Michael Wonder on 23 Apr 2024
ICER and NEWDIGS release white paper analysing the challenges and potential policy options for paying for gene therapies
23 April 2024 - Paper outlines policy reforms and market actions to support innovation and access while managing uncertainty, affordability, ...
Posted by Michael Wonder on 09 Apr 2024
ICER publishes 2024 research protocol for assessing unsupported price increases on prescription drugs
9 April 2024 - Input period now open until 13 May 2024. ...
Posted by Michael Wonder on 11 Dec 2023
ICER identifies most significant 2022 US drug price hikes unsupported by new clinical evidence
11 December 2023 - Of 10 high expenditure drugs that had substantial 2022 net price increases, eight were not supported by ...
Posted by Michael Wonder on 02 Oct 2023
ICER publishes special report on Eliquis and Xarelto submitted to CMS as part of public comment process on Medicare drug price negotiations
2 October 2023 - Report tailored to reflect legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding ...
Posted by Michael Wonder on 21 Jun 2023
ICER receives grant from The Commonwealth Fund for annual assessment of coverage policies that present barriers to fair access
21 June 2023 - ICER’s third annual “Barriers to Fair Access” report will be published in November 2023. ...